BriaCell Therapeutics Corp.

09/08/2026

“We are pleased to welcome MSK as a clinical site in BriaCell’s Phase 3 study,” stated Dr. William V. Williams, BriaCell’s President & CEO. Learn more about BriaCell's pivotal Phase 3 study in : https://bit.ly/4yo8VyT

09/08/2026

BriaCell (Nasdaq: BCTX, BCTXL) (TSX: BCT) announced that Memorial Sloan Kettering Cancer Center (MSK) has joined BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT™ plus an immune checkpoint inhibitor in metastatic breast cancer (ClinicalTrials.gov identifier: NCT06072612). Find details: https://feeds.issuerdirect.com/news-release.html?newsid=5184316962761549&symbol=BCTX

09/03/2026

We’re Hiring at BriaCell!

Join a team advancing innovative cancer immunotherapies and helping bring new treatment approaches to patients.

Current Openings:
• Scientist/Senior Scientist – QC – Philadelphia, USA
• Scientist – Translational Biomarkers & Immunomonitoring
• Clinical Research Associate Intern

If you’re passionate about oncology, biotechnology and advancing the future of cancer treatment, we’d love to hear from you.

Explore the opportunities and apply: briacell.com/careers/

09/03/2026

In a guest column for Drug Discovery Online, BriaCell CEO William V. Williams, MD, FACP, discusses the path to personalized scalable solid tumor immunotherapies. Read the full article: https://bit.ly/4gLkU2p

Translating early momentum into accessible, scalable therapies for refractory solid tumors requires prioritizing multitargeted off-the-shelf platforms at the preclinical stage.

09/02/2026

BriaCell is expanding its personalized, cell-based approach across multiple cancer indications.

In a new Inside Precision Medicine article, Bria-MEL+, BriaCell's personalized whole cell immunotherapy vaccine candidate is highlighted alongside BriaCell’s Phase 3 trial of Bria-IMT™ in metastatic breast cancer and Bria-PROS+ in prostate cancer.

Read more: https://bit.ly/46u9Guc

BriaCell has that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a “key genetic engineering milestone, advancing the program toward clinical development."

09/02/2026

“The future of cellular oncology lies in off-the-shelf, targeted platforms.”

In a new PharmaPhorum article, BriaCell President & CEO William V. Williams examines the innovation gap in oncology and the need for scalable approaches to cellular immunotherapy.

The article explores how off-the-shelf cell platforms could reduce production costs, lower health system burdens and eliminate critical treatment delays, while next-generation whole-cell and platform approaches may help address the complex, immunosuppressive environments of solid tumours.

Dr. Williams also discusses adaptive clinical trial protocols and the importance of aligning early clinical strategies with the realities of late-stage development and commercialisation.

Read the full article: https://bit.ly/4ygcKWD

Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.

09/01/2026

Explore Your Next Opportunity at BriaCell.

At BriaCell Therapeutics, our team is working to advance innovative cancer treatments and make a meaningful impact in oncology.

Current openings include:

• Scientist/Senior Scientist – QC – Philadelphia, USA
• Scientist (Translational Biomarkers & Immunomonitoring)
• Clinical Research Associate Intern

Interested in being part of the team? View open positions and learn more: briacell.com/careers/

08/31/2026

September is Prostate Cancer Awareness Month, a timely reminder of the urgent need for advanced treatment options.

With FDA clearance of our IND application for Bria-PROS+™, our team is preparing to initiate a Phase 1/2a clinical trial. Bria-PROS+™ is our next-generation, off-the-shelf, personalized cell-based immunotherapy designed to activate the body's immune system against advanced prostate cancer.

As September approaches, our commitment to delivering innovative immuno-oncology solutions to patients who need them most is stronger than ever.

Learn more here: https://bit.ly/4fNH4An

08/28/2026

ICYMI: BriaCell is advancing Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate, toward clinical development following a key genetic engineering milestone.

Bria-MEL+ is designed to be personalized yet “off-the-shelf”: a simple patient saliva test will determine which of several premanufactured treatment cell lines will be selected for personalized treatment, avoiding the need to manufacture a unique product for each individual patient.

For more: https://bit.ly/4xjGX7p

08/28/2026

As personalized cancer vaccines gain momentum, BriaCell is advancing a distinct approach with Bria-MEL+.

As highlighted by Inside Precision Medicine, Bria-MEL+ is designed as a personalized, off-the-shelf cellular immunotherapy for melanoma—using a simple saliva test to identify the premanufactured cell line selected through patient HLA matching.

Read the full article: https://bit.ly/46u9Guc

BriaCell has that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a “key genetic engineering milestone, advancing the program toward clinical development."